Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Drug Developed in U.K. to Treat Solid Tumors

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
Cancer Research U.K.'s Drug Development Office; Cancer Research Technology, and Lorus Therapeutics Inc. have partnered to take a new therapy with the potential to treat solid tumors into its first clinical trial.

The treatment, IL-17E, is a type of protein called a pro-inflammatory cytokine which, according to research done at Lorus, is thought to elicit an immune response which attacks cancer cells, and determining exactly how it does this will form part of the work being done. It incorporates technology owned by both Lorus and Genentech, after Lorus scientists discovered the anticancer properties of IL-17E against a range of solid tumors.

Cancer Research U.K.'s Clinical Development Partnerships (CDP) is a joint initiative between Cancer Research UK's Drug Development Office (DDO) and Cancer Research Technology. The partnership seeks to develop promising anticancer agents that may not otherwise be developed, and take them through preclinical development and early clinical trials.

With the CDP scheme, companies retain the background rights to their programs while enabling Cancer Research U.K. to take on early development work to evaluate the benefit to cancer patients. Three drugs are now in clinical trials with others scheduled to open in early 2013.

Cancer Research U.K.'s DDO will fund and undertake extensive preclinical work led by Professor Christian Ottensmeier at the University of Southampton, England, to further investigate the mechanism by which the protein destroys cancer cells and to further develop the drug for use in treating cancer patients.

The DDO will then fund, manage, and sponsor the first Phase I clinical trial led by Professor Chris Twelves and Dr. Christy Ralph at the Cancer Research U.K./NIHR Leeds Experimental Cancer Medicine Centre, based at the University of Leeds, England. Lorus will manufacture and supply IL-17E for the non-clinical toxicology and Phase I clinical studies.

After the Phase I trial, Lorus will have the exclusive option to license the Phase I clinical trial data and resume further clinical development. If it does not exercise this option, the rights to the program would be transferred to Cancer Research Technology to secure an alternative partner, with the aim to make the treatment available for cancer patients while Lorus would retain certain economic interests.

IL-17E was selected following a rigorous peer-review process conducted by Cancer Research U.K.'s New Agents Committee (NAC). Assessment of IL-17E by the NAC was based on several criteria, including scientific rationale, quality of the anticancer data in relevant tumor models, novelty, and clinical need. IL-17E is the eighth treatment to enter Cancer Research U.K.'s Clinical Development Partnerships scheme.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cancer Research UK, TYG Oncology Partner
Cancer Research UK and CRT have signed an agreement with TYG oncology to take its new cancer vaccine TYG100 into clinical trials.
Monday, November 07, 2016
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Tuesday, September 06, 2016
Cancer Research UK, Cancer Research Technology And Asterias Biotherapeutics Partner
Partnership Developed to Trial Immunotherapy Vaccine For Lung Cancer
Friday, September 12, 2014
Cancer Research UK, AZ and Pfizer Partner to Advance Lung Cancer Treatment
Partnership creates a pioneering clinical trial for patients with advanced lung cancer, marking a new era of research into personalised medicines to treat cancer.
Thursday, April 17, 2014
Final Results from the Phase III TeloVac Trial in Pancreatic Cancer
Results from the trial showed no significant difference in overall survival between the groups that received the vaccine and the control group receiving chemotherapy.
Tuesday, June 04, 2013
Astronomy Algorithms Help Diagnose Aggressive Tumors
Scientists have honed techniques originally developed to spot distant galaxies and used them to identify biomarkers that signal a cancer’s aggressiveness among some 2,000 breast tumours.
Monday, February 25, 2013
Scientists Find New Drug Target for Hard-to-Treat Leukaemia
Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival.
Friday, March 30, 2012
Cancer Research UK Launches Medicine Manufacturing Hub for Life-Saving Research
New £18 million drug manufacturing facility will make experimental medicine and antibodies to target cancer cells.
Tuesday, August 03, 2010
immatics Enters Collaboration with Cancer Research UK to Develop Cancer Vaccine
Cancer Research UK will sponsor and conduct a Phase I trial of IMA950 for glioblastoma.
Wednesday, February 17, 2010
Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine
IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer
Tuesday, February 16, 2010
Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!